Gilead Sciences, Inc. reported a significant decline in profitability for the second quarter of 2026, with a net loss of $10.5 billion, compared to a net income of $2.0 billion in the same period last year. This resulted in a diluted loss per share of $8.45, a stark contrast to the earnings of $1.56 per share recorded in the prior year. The company's total revenues increased by 10% to $7.8 billion, driven primarily by higher sales of HIV products, including Biktarvy and Descovy, as well as contributions from Trodelvy and Livdelzi. However, these gains were offset by substantial costs associated with recent acquisitions and impairments.

The financial results reflect a notable increase in costs, particularly in research and development (R&D) and acquired in-process research and development (IPR&D) expenses. R&D expenses rose 18% to $1.8 billion, while IPR&D expenses surged to $11.2 billion, largely due to the acquisitions of Arcellx, Tubulis, and Ouro Medicines. Additionally, Gilead recognized a $1.75 billion impairment charge related to previously acquired IPR&D assets, which significantly impacted the bottom line.

Operationally, Gilead's product sales for the three months ended June 30, 2026, reached $7.6 billion, up from $7.1 billion in the same quarter of 2025. The HIV segment alone accounted for $5.7 billion in sales, reflecting a 12% increase year-over-year. Notably, sales of Biktarvy increased by 7%, while Descovy saw a substantial 48% rise. However, sales of Veklury, the company's COVID-19 treatment, plummeted by 81% due to decreased hospitalization rates.

In terms of strategic developments, Gilead completed several significant acquisitions in 2026, including Tubulis and Arcellx, which are expected to enhance its oncology portfolio. The company also received FDA approvals for key products, including Hepcludex for hepatitis delta virus and Trodelvy for breast cancer treatment. Looking ahead, Gilead anticipates continued revenue growth driven by its HIV and oncology products, although it remains cautious about the impact of ongoing market conditions and integration costs from its recent acquisitions.

About GILEAD SCIENCES, INC.

Gilead Sciences, Inc. is a biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for unmet medical needs. Its core areas include virology, oncology, and inflammation, with key products for HIV, hepatitis, COVID-19, and cancer. Operating globally, Gilead emphasizes first-in-class therapies, strategic collaborations, and a strong patent portfolio to maintain competitive advantage and improve patient outcomes.

This description was generated via AI from an annual report. Updated about 1 year ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.

View the complete official filing on the SEC website.

Read on SEC.gov